Tyrosine Kinase
Transforming Glaucoma Care With Rho Kinase Inhibitors
This activity is supported by an educational grant from Alcon Vision, LLC.
Tyrosine Kinase Inhibitors: Transforming nAMD Treatment
This activity is supported by an educational grant from EyePoint Pharmaceuticals, Inc.
Tyrosine Kinase Inhibitors and Their Role in Redefining Retinal Care
This activity is supported by an educational grant from Ocular Therapeutix, Inc.
VIDEO: Over two dozen vasculitis drugs in development
In this video, Rula Hajj-Ali, MD discusses the state of the pipeline for developing vasculitis treatments.
VIDEO: Bruton tyrosine kinase inhibitor studied in immune thrombocytopenia
In this video, Ronak Mistry, DO, discusses the results of a study presented at ASH Annual Meeting that examined the use of the Bruton tyrosine kinase inhibitor rilzabrutinib in patients with immune thrombocytopenic purpura.
Oral zasocitinib presents high potential as new psoriasis treatment
Zasocitinib, a potent and selective tyrosine kinase 2 inhibitor, safely and effectively cleared psoriasis in a high proportion of patients, according to a study.
Biopharma firm raises $30M to advance neuro, derm tyrosine kinase 2 inhibitors
An Indianapolis-area biopharmaceutical company announced it has raised $30 million in Series B financing to advance investigational tyrosine kinase 2 inhibitors for multiple sclerosis as well as dermatologic conditions.
Cancer drug class associated with high risk for cardiovascular adverse events
SAN DIEGO — Individuals treated with first-generation Bruton tyrosine kinase inhibitors with preexisting cardiovascular disease had significantly higher odds of developing cardiovascular adverse events, study results showed.
Oral brepocitinib fails to meet primary endpoint in phase 2 lupus study
Oral brepocitinib failed to meet its primary endpoint in a phase 2 trial of adults with moderate to severe lupus, according to a press release from the manufacturer.
VIDEO: Novel tyrosine kinase 2 inhibitor ‘potentially’ effective in psoriasis treatment
In this Healio video exclusive, Jashin J. Wu, MD, FAAD, covers a presentation from the American Academy of Dermatology Annual Meeting on TAK-279, a tyrosine kinase 2 inhibitor, in the treatment of individuals with severe psoriasis.